- Experimental Alzheimer’s drug slows cognitive decline in large trial, drugmaker Eli Lilly saysCNN
- Donanemab, Eli Lilly’s Alzheimer’s treatment, slowed disease progression in clinical trialCNBC
- Livebarrons
- Experimental drug slows Alzheimer’s disease in large study, says Eli LillyThe Wall Street Journal
- Lilly’s donanemab significantly slowed cognitive and functional decline in a phase 3 study in early-onset Alzheimer’s disease | Eli Lilly and companyInvestors | Eli Lilly and company
- See full coverage on Google News